Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis with F508del mutation
NCT03525574Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Oct 2018; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03525574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525574.